Retatrutide

Retatrutide may be the most potent weight-loss molecule ever tested in humans. In a Phase 2 clinical trial, participants receiving the highest dose lost an average of 24.2% of their body weight over 48 weeks — and the weight-loss curve had not yet plateaued, meaning the final number could have been higher with a longer trial. No other pharmaceutical agent, including semaglutide and tirzepatide, has come close to this figure in a controlled clinical setting.

What makes retatrutide different is its mechanism. While semaglutide is a pure GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist, retatrutide is a triple agonist — simultaneously activating the GIP receptor, the GLP-1 receptor, and the glucagon receptor. The addition of glucagon agonism introduces an entirely new metabolic lever: increased energy expenditure and enhanced hepatic fat oxidation, stacked on top of the appetite suppression provided by GLP-1 and GIP agonism.

Developed by Eli Lilly under the research designation LY3437943, retatrutide is currently in Phase 3 clinical trials. It is not yet FDA-approved. TriedRx tracks 48 vendors and 312 samples of retatrutide in the research peptide market.

How Retatrutide Works: Triple Agonism

Understanding retatrutide requires understanding what each of its three receptor targets contributes.

GLP-1 Receptor Agonism

The GLP-1 component provides the appetite-suppressive backbone shared by all drugs in the GLP-1 peptide category:

• Centrally mediated appetite suppression via hypothalamic and brainstem GLP-1 receptors
• Glucose-dependent insulin secretion
• Glucagon suppression from alpha cells
• Delayed gastric emptying

This is the same mechanism that drives semaglutide's efficacy. In retatrutide, it represents one-third of the pharmacological story.

[CITATION: PubMed study needed on GLP-1 receptor contribution to retatrutide's mechanism of action]

GIP Receptor Agonism

The GIP component mirrors the dual-agonist approach pioneered by tirzepatide:

• Enhanced lipid metabolism in adipose tissue
• Complementary appetite modulation through distinct brain circuits
• Potential mitigation of GLP-1-mediated nausea
• Improved insulin sensitivity through adipose tissue signaling

GIP receptor agonism appears to synergize with GLP-1 agonism, producing greater weight loss and metabolic improvement than either alone. Tirzepatide demonstrated this principle clinically, and retatrutide extends it further.

[CITATION: PubMed study needed on GIP receptor role in triple agonist pharmacology]

Glucagon Receptor Agonism: The New Variable

This is what sets retatrutide apart. Glucagon — the hormone that raises blood sugar — seems like a counterintuitive target for a diabetes and obesity drug. But glucagon receptor activation produces metabolic effects that complement incretin agonism:

Increased energy expenditure: Glucagon stimulates thermogenesis and increases resting metabolic rate. While GLP-1 and GIP agonism primarily reduce energy intake (calories consumed), glucagon agonism increases energy output (calories burned). This dual approach — suppressing intake while boosting expenditure — may explain retatrutide's superior efficacy.

Hepatic fat oxidation: Glucagon promotes fatty acid oxidation in the liver, reducing hepatic fat content. This has profound implications for metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), where retatrutide's Phase 2 data showed dramatic liver fat reductions.

Amino acid metabolism: Glucagon stimulates hepatic amino acid catabolism and ureagenesis. The metabolic significance of this in the context of obesity treatment is still being studied.

[CITATION: PubMed study needed on glucagon receptor agonism effects on energy expenditure and hepatic fat metabolism]

The glycemic paradox: The obvious concern with glucagon agonism is hyperglycemia — glucagon raises blood sugar. In retatrutide, this effect is counterbalanced by the potent glucose-lowering activity of the GLP-1 and GIP components. The net glycemic effect in clinical trials has been glucose-lowering, not glucose-raising, demonstrating that the incretin activity dominates. However, careful dose-finding was necessary to achieve this balance.

[CITATION: PubMed study needed on glycemic balance in triple agonist compounds — retatrutide glucose data]

Molecular Design

Retatrutide is a 39-amino-acid peptide with a fatty acid modification for albumin binding and extended half-life. It was engineered through structure-activity relationship studies to achieve specific affinity ratios at each of its three target receptors. The relative potency at each receptor is a critical design parameter — too much glucagon agonism would cause hyperglycemia; too little would forfeit the energy expenditure benefit.

[CITATION: PubMed study needed on retatrutide molecular structure and receptor affinity ratios]

Clinical Trial Data

Phase 2 Trial: The 24% Weight Loss

The Phase 2 trial that put retatrutide on the map was published in the New England Journal of Medicine in 2023:

• Population: 338 adults with BMI >= 30 (or >= 27 with at least one comorbidity), without type 2 diabetes
• Design: Randomized, double-blind, placebo-controlled, dose-finding
• Duration: 48 weeks
• Arms: Multiple retatrutide doses (1mg, 4mg, 8mg, 12mg) and placebo
• Results:
• 1mg: -8.7% body weight loss
• 4mg: -17.1% body weight loss
• 8mg: -22.8% body weight loss
• 12mg: -24.2% body weight loss (vs. -2.1% placebo)
• At 12mg, 26% of participants achieved >= 30% weight loss

[CITATION: PubMed study needed on retatrutide Phase 2 obesity trial — Jastreboff et al., NEJM 2023]

Critical context: The weight-loss curve at 48 weeks had not plateaued, meaning participants were still actively losing weight when the trial ended. This suggests that the ultimate weight loss with continued treatment could exceed 24%. By comparison, semaglutide's weight-loss curve in STEP 1 plateaued at approximately 60-68 weeks, and tirzepatide's in SURMOUNT-1 was approaching plateau at 72 weeks.

Phase 2 Diabetes Trial

A separate Phase 2 trial evaluated retatrutide in adults with type 2 diabetes:

• Population: 281 adults with type 2 diabetes and BMI >= 25
• Results: Retatrutide at 12mg reduced HbA1c by -2.02% and body weight by -16.9% over 36 weeks. Notably, 71.4% of participants receiving 12mg achieved HbA1c < 5.7% (non-diabetic range).

[CITATION: PubMed study needed on retatrutide Phase 2 diabetes trial results]

MASLD/MASH Data

Perhaps the most striking secondary finding from retatrutide's Phase 2 program was its effect on liver fat:

• In a sub-study using MRI-based proton density fat fraction (PDFF), retatrutide at 12mg reduced liver fat by an average of 82-86% over 48 weeks.
• 93% of participants with MASLD at baseline achieved liver fat normalization (PDFF < 5%).

[CITATION: PubMed study needed on retatrutide liver fat reduction data from Phase 2 trial]

These numbers far exceed anything previously demonstrated with GLP-1 mono-agonists or dual agonists, likely due to glucagon receptor-mediated hepatic fat oxidation. A dedicated Phase 3 trial of retatrutide for MASH is underway.

Phase 3 Program

Eli Lilly's Phase 3 program for retatrutide includes multiple trials:

• TRIUMPH-1: Retatrutide vs. placebo in adults with obesity without diabetes (primary weight-management trial)
• TRIUMPH-2: Retatrutide vs. placebo in adults with obesity and type 2 diabetes
• TRIUMPH-3: Retatrutide for MASH

Results from these trials are expected between 2025 and 2027, with a potential FDA submission to follow.

Dosing: What Research Has Examined

Because retatrutide is not yet FDA-approved, there is no established prescribing protocol. The Phase 2 trial used a dose-escalation schedule:

• Weeks 1-4: Starting dose (varied by arm: 1mg, 2mg, or 4mg)
• Dose escalation every 4 weeks by 2mg increments (in the 8mg and 12mg arms)
• Target maintenance dose: 8mg or 12mg once weekly

Research has examined that the 12mg dose produced the greatest weight loss but also the highest incidence of gastrointestinal adverse events. The 8mg dose offered a meaningful reduction in GI symptoms while still producing 22.8% weight loss — only 1.4 percentage points less than the highest dose.

[CITATION: PubMed study needed on retatrutide dose-response and tolerability by dose level]

Side Effects and Safety

Common Side Effects

The side-effect profile in Phase 2 was broadly consistent with other GLP-1 agonists, with gastrointestinal effects predominating:

[CITATION: PubMed study needed on retatrutide Phase 2 adverse event data by dose]

The discontinuation rate due to adverse events was 6% at the highest dose — comparable to tirzepatide and slightly lower than semaglutide, despite retatrutide producing substantially more weight loss.

Glucagon-Specific Safety Considerations

The glucagon agonist component introduces unique safety considerations not present with pure GLP-1 or dual GIP/GLP-1 agonists:

Heart rate: Glucagon can increase heart rate. In the Phase 2 trial, retatrutide at 12mg was associated with a small increase in resting heart rate (~3-4 bpm). This is slightly higher than the ~2 bpm increase seen with semaglutide and tirzepatide. The clinical significance is uncertain but warrants monitoring in the Phase 3 program.

[CITATION: PubMed study needed on retatrutide heart rate effects in Phase 2]

Hepatic effects: While glucagon-mediated liver fat reduction is beneficial for MASLD, there is a theoretical concern about chronic glucagon stimulation affecting hepatic protein synthesis or bile acid metabolism. Phase 2 data did not reveal liver safety signals, but Phase 3 trials will provide larger datasets.

Blood glucose: In the non-diabetic population, retatrutide did not cause clinically significant hypoglycemia despite the glucose-lowering effects of its GLP-1 and GIP components. In the diabetic population, hypoglycemia was observed at higher rates when combined with insulin or sulfonylureas — similar to other incretin-based therapies.

Standard GLP-1 Class Warnings

Like all GLP-1 receptor agonists, retatrutide Phase 2 data carried the standard precautions regarding:

• Pancreatitis (rare events reported)
• Gallbladder events (cholelithiasis observed at elevated rates vs. placebo)
• Thyroid C-cell tumors (preclinical monitoring ongoing; boxed warning anticipated if approved)

Drug Interactions

Formal drug interaction studies for retatrutide are limited at this stage of development. Based on its GLP-1 agonist mechanism, the same gastric emptying-related interactions observed with semaglutide and tirzepatide should be anticipated:

• Altered absorption of oral medications with narrow therapeutic windows
• Increased hypoglycemia risk with insulin and sulfonylureas
• Potential effects on oral contraceptive efficacy

The glucagon component may introduce additional interactions related to hepatic metabolism, but these have not yet been characterized in formal pharmacokinetic studies.

[CITATION: PubMed study needed on anticipated drug interactions with triple agonist peptides]

Legal Status

Retatrutide is not FDA-approved. It is currently in Phase 3 clinical trials. No regulatory submission has been filed as of April 2026.

Research market: Retatrutide is available from research peptide vendors as a "research chemical" — sold for laboratory research purposes only, not for human use. TriedRx tracks 48 vendors and 312 samples in this category. The legal status of purchasing research peptides varies by jurisdiction but generally occupies a gray area.

Clinical trial access: Patients may access retatrutide through enrollment in Eli Lilly's Phase 3 TRIUMPH trials. Clinical trial listings are available through ClinicalTrials.gov.

Compounding: Because retatrutide has no FDA-approved version, it cannot be legally compounded under the drug shortage provisions that apply to semaglutide and tirzepatide. Products sold as "compounded retatrutide" exist in a legally precarious position.

Who Should Watch Retatrutide

Retatrutide is not currently available for clinical use outside of trials. However, it is of particular interest to:

• Patients who have achieved suboptimal responses to semaglutide or tirzepatide
• Patients with concurrent obesity and MASLD/MASH, where retatrutide's liver-fat-reducing effects could be particularly valuable
• Clinicians tracking the frontier of anti-obesity pharmacotherapy
• Researchers interested in the metabolic effects of glucagon receptor agonism

Who Should Approach With Caution

Even once approved, retatrutide may not be appropriate for:

• Patients with type 1 diabetes or insulin-dependent type 2 diabetes (glucagon agonism could complicate glycemic management)
• Patients with cardiac arrhythmias or conditions sensitive to heart rate increases
• Patients with personal or family history of MTC or MEN2 (anticipated contraindication based on GLP-1R component)
• Patients with active hepatic disease beyond MASLD (until liver safety data from Phase 3 is available)
• Pregnant or planning pregnancy

For a comparison of all GLP-1 and multi-agonist agents, see our GLP-1 Peptide Category Guide. For information on currently available alternatives, see our profiles of semaglutide and tirzepatide. To understand how the next wave of oral agents could reshape the landscape, see Orforglipron.